Week of November 19, 2012: German Court Finds AstraZeneca's Seroquel XR Formulation Patent Invalid; FDA Advisory Committee to Recommend Approval of GSK's H5N1 Influenza Vaccine Candidate; and More - P

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of November 19, 2012: German Court Finds AstraZeneca's Seroquel XR Formulation Patent Invalid; FDA Advisory Committee to Recommend Approval of GSK's H5N1 Influenza Vaccine Candidate; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

The Federal Patent Court in Germany has found the formulation patent protecting AstraZeneca’s Seroquel XR (quetiapine fumarate) prolonged-release tablets–marketed as Seroquel Prolong in Germany–to be invalid. The patent was challenged by Accord Healthcare, Hexal, and Teva Deutschland. The Federal Patent Court decision is limited to Germany and is not binding in other countries. AstraZeneca is engaged in numerous other proceedings regarding Seroquel XR-related patents and regulatory exclusivity for Seroquel XR. Further updates will be provided on a quarterly basis as part of the company’s earnings report. Total sales of Seroquel XR in Germany for the ten months, ending on Oct., 31 2012, were $82 million. Read More

GlaxoSmithKline (GSK) announced FDA’s Vaccines and Related Biological Products Advisory Committee voted unanimously 14–0 that the safety and immunogenicity data of the H5N1 adjuvanted influenza vaccine candidate supports its licensure for the active immunization for the prevention of disease in persons 18 years of age and older who are at increased risk of exposure to the influenza A virus H5N1 subtype contained in the vaccine. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here